Suboxone vs Sublocade

How they're similar

Both formulations are buprenorphine, so they share the core mechanism and most of the safety profile.

• Both are partial mu-opioid agonists with a ceiling effect on respiratory depression, meaning a safer overdose profile than methadone or full agonist opioids.
• Both treat opioid use disorder. Both reduce cravings, prevent withdrawal, and cut overdose death.
• Both can be prescribed by any DEA-registered clinician since the X-waiver was eliminated in 2023.
• Both have the same interaction concerns and the same risks in patients using benzos or alcohol, since combining opioids with those drugs raises overdose risk even for buprenorphine.
• Both can cause constipation, sweating, headache, and sedation, though in stable patients on a stable dose these are usually mild.
• Both can suppress testosterone or estrogen with long-term use.
• Both work best combined with behavioral support, though the medication alone still helps.

The point is that switching between them isn't switching medications. It's switching how the same medication is delivered.

How they differ

The delivery difference drives everything else. The table below covers the core points.

Suboxone is a sublingual film or tablet. It's placed under the tongue and dissolves over several minutes. It contains buprenorphine combined with naloxone, usually in a 4 to 1 ratio. The naloxone is added to deter injection misuse. Naloxone is poorly absorbed through the mouth, so it doesn't do much when the film is used correctly. If someone tries to dissolve and inject the film, the naloxone becomes active and precipitates withdrawal. That's the deterrent. Daily dosing means the patient makes an active choice every day to take the medication, and daily levels can dip if a dose is missed or timed poorly.

Sublocade is a subcutaneous injection that releases buprenorphine slowly over about a month. The starting dose is 300 mg for the first two months, then either 100 mg or 300 mg monthly for maintenance depending on how the patient is doing. The injection is given in the abdomen, and it forms a small depot under the skin that releases medication gradually. Because the release is slow and steady, the blood level stays relatively flat across the month. That's part of why it works so well for cravings. There's no daily dip, and there's no daily choice to make.

Sublocade has to be given in a healthcare setting under a program called REMS (Risk Evaluation and Mitigation Strategy). The reason is that direct IV injection of the product can cause serious harm, so it can't be dispensed to patients directly. The clinic or pharmacy that gives the injection has to be enrolled in the REMS program. This isn't hard for most clinics, but it's an added step.

The starting requirement is different. Suboxone can be started from scratch with a traditional induction: the patient goes into mild to moderate withdrawal, takes a small first dose, and titrates up over hours to a stable dose. Sublocade can't be started from scratch. The patient has to be on transmucosal buprenorphine, which means Suboxone or another sublingual form, for at least 7 days at a stable dose before the first Sublocade injection. This is to make sure buprenorphine is tolerated and to ease the transition without precipitated withdrawal.

Stopping is different too. Suboxone levels drop within a few days of the last dose. If a patient stops, they'll be back into withdrawal within a day or two. Sublocade levels persist for months after the last injection because the depot keeps releasing medication for a long time. That's a benefit if adherence is a problem, since a patient who misses their next appointment is still protected for weeks. It's a downside if the patient wants to stop, needs surgery, or has to be off buprenorphine for another reason, because the medication doesn't go away quickly.

Cost is the elephant in the room. Generic Suboxone film is relatively inexpensive and covered by most insurance under the pharmacy benefit. Sublocade is significantly more expensive, sometimes several times the cost of a month of Suboxone. It's usually billed as a medical benefit rather than a pharmacy benefit because it's administered in a healthcare setting, and coverage varies. Prior authorization is common, and access can be a real barrier for uninsured patients.

Misuse potential is different. Suboxone film is diverted at some rate, though the naloxone helps deter injection. Sublocade is essentially undiverted because it's only given under REMS and only in a clinical setting.

Side effect tendencies

Because both are buprenorphine, the everyday side effects are similar. Constipation, headache, sweating, and mild sedation are common with both, especially early. Long-term use of either can suppress testosterone or estrogen and affect mood, energy, and sexual function.

Sublocade adds one specific issue: the injection site. A small firm bump forms under the skin where the depot releases, and it stays there for the month. Some patients have pain, itching, or bruising at the site. The injection is rotated between sides of the abdomen for each dose. Injection site reactions are usually mild but occasionally more significant.

Sublocade also has one benefit for tolerability that gets underrated. Because the level is steady across the month, some patients feel more even than they did on daily Suboxone. On Suboxone, some patients feel a small dip toward the end of the day or in the morning before the next dose. On Sublocade, that pattern is gone.

Suboxone film has the sublingual issues that come with any long-term sublingual product. Dry mouth is common, and there's a signal in the data linking long-term buprenorphine film to dental problems. Current guidance recommends good oral hygiene, rinsing the mouth with water after the film dissolves, and regular dental check-ins.

What tips the choice

For most patients starting treatment for opioid use disorder, Suboxone is the more common first choice. It's easier to start, easier to adjust, and doesn't require a healthcare-setting appointment for every dose. Once a patient is stable on Suboxone, the question of whether to move to Sublocade comes up in specific situations.

Sublocade tends to be chosen when adherence is a real problem, when the patient wants the monthly structure, when frequent dosing dips make cravings harder to manage, or when the risk of losing daily medication is high. Some patients feel more stable on Sublocade because the medication is decided for the month and not renegotiated every day. For patients with a history of relapse driven by adherence failures, Sublocade can be a real game-changer.

A few concrete scenarios. A 30-year-old starting treatment for the first time is a natural Suboxone start. If they're stable after several months and want to move to a less demanding schedule, Sublocade is reasonable. A patient who has relapsed multiple times after stopping Suboxone might be a strong Sublocade candidate, since the monthly schedule takes the daily decision off the table. A patient with unpredictable insurance coverage or in the process of losing coverage may do better on Suboxone since it's cheaper and doesn't require billing a medical benefit. A patient who wants to eventually taper off buprenorphine may prefer Suboxone, since Sublocade's long tail makes tapering harder.

Common questions

Can I switch from Suboxone to Sublocade, or the other way around? Yes, and switching either direction is done routinely. To go from Suboxone to Sublocade, the patient continues Suboxone until the day of the first injection, and Suboxone is stopped the day of. The Sublocade takes over. To go from Sublocade back to Suboxone, the timing depends on when the last injection was given and how much medication is still in the depot. Because Sublocade releases slowly, Suboxone usually isn't needed for weeks after the last injection. The transition is planned with the prescriber.

Why is Sublocade so expensive? Because it's an extended-release injectable product delivered under a REMS program, and generic competition doesn't exist yet. The cost includes not just the medication but the healthcare visit for administration. Coverage varies, and prior authorization is common. For patients with good insurance, out-of-pocket cost can be reasonable. For patients without coverage, it's often out of reach without patient assistance programs, which the manufacturer runs.

What happens if I miss a Sublocade injection? Because the medication persists in the depot for weeks after the last dose, missing an appointment by a week or two usually doesn't cause immediate withdrawal. Missing by longer than that can. If a patient knows they'll be late, the injection can often be scheduled slightly early or slightly late without a problem, but the schedule should be worked out with the prescriber. Some patients who miss the injection go back on Suboxone temporarily to bridge until the next dose.

Is the naloxone in Suboxone doing anything if I take it correctly? Not really. Naloxone is poorly absorbed through the mouth, so when the film dissolves under the tongue, almost none of the naloxone gets into the blood. It's added to deter injection, because if someone dissolves and injects the film, the naloxone becomes active and causes withdrawal. In normal daily use, patients get the effect of the buprenorphine only, and the naloxone doesn't matter.

Can I still work and drive on either of these? Yes. On a stable dose of either form, most patients don't feel sedated and can work, drive, and take care of their families normally. Sedation is more common at the very start, during induction, and eases within the first week or two. Combining buprenorphine with benzos, alcohol, or other sedating drugs is where sedation and risk go up sharply, which is why those combinations get careful attention.

Sources

This guide draws on current prescribing information and public health references. It is reviewed for clinical accuracy and updated as guidance changes.

1. U.S. Food and Drug Administration. Suboxone prescribing information.
2. U.S. Food and Drug Administration. Sublocade prescribing information.
3. Substance Abuse and Mental Health Services Administration. Medications for opioid use disorder.
4. American Society of Addiction Medicine. National practice guideline for the treatment of opioid use disorder.
5. National Institute on Drug Abuse. Medications to treat opioid use disorder research report.